Unknown

Dataset Information

0

The Role of Receptor Tyrosine Kinases in Lassa Virus Cell Entry.


ABSTRACT: The zoonotic Old World mammarenavirus Lassa (LASV) causes severe hemorrhagic fever with high mortality and morbidity in humans in endemic regions. The development of effective strategies to combat LASV infections is of high priority, given the lack of a licensed vaccine and restriction on available treatment to off-label use of ribavirin. A better understanding of the fundamental aspects of the virus's life cycle would help to improve the development of novel therapeutic approaches. Host cell entry and restriction factors represent major barriers for emerging viruses and are promising targets for therapeutic intervention. In addition to the LASV main receptor, the extracellular matrix molecule dystroglycan (DG), the phosphatidylserine-binding receptors of the Tyro3/Axl/Mer (TAM), and T cell immunoglobulin and mucin receptor (TIM) families are potential alternative receptors of LASV infection. Therefore, the relative contributions of candidate receptors to LASV entry into a particular human cell type are a complex function of receptor expression and functional DG availability. Here, we describe the role of two receptor tyrosine kinases (RTKs), Axl and hepatocyte growth factor receptor (HGFR), in the presence and absence of glycosylated DG for LASV entry. We found that both RTKs participated in the macropinocytosis-related LASV entry and, regardless of the presence or absence of functional DG, their inhibition resulted in a significant antiviral effect.

SUBMITTER: Fedeli C 

PROVIDER: S-EPMC7472032 | biostudies-literature | 2020 Aug

REPOSITORIES: biostudies-literature

altmetric image

Publications

The Role of Receptor Tyrosine Kinases in Lassa Virus Cell Entry.

Fedeli Chiara C   Moreno Hector H   Kunz Stefan S  

Viruses 20200806 8


The zoonotic Old World mammarenavirus Lassa (LASV) causes severe hemorrhagic fever with high mortality and morbidity in humans in endemic regions. The development of effective strategies to combat LASV infections is of high priority, given the lack of a licensed vaccine and restriction on available treatment to off-label use of ribavirin. A better understanding of the fundamental aspects of the virus's life cycle would help to improve the development of novel therapeutic approaches. Host cell en  ...[more]

Similar Datasets

| S-EPMC4239993 | biostudies-literature
| S-EPMC2655582 | biostudies-literature
| S-EPMC2914105 | biostudies-literature
| S-EPMC3302412 | biostudies-literature
| S-EPMC4929682 | biostudies-literature
| S-EPMC8103687 | biostudies-literature
| S-EPMC4092852 | biostudies-literature
| S-EPMC6179309 | biostudies-literature
| S-EPMC6069209 | biostudies-literature
| S-EPMC3100575 | biostudies-literature